Log in
The work of Colledge and colleagues between 2000 and 2007 has identified and characterised a molecule which is an important regulator of fertility: the neuropeptide kisspeptin.
The identification of its role in fertility has led to kisspeptin and its analogues being tested in clinical trials to make IVF treatment safer (Phase II: one trial), and as therapeutic agents for reproductive system conditions such as delayed puberty, menopause and absence of menstruation (Phase I: four trials). In April 2013, 11 months after the start of the Phase II IVF study, a healthy baby has been born to a participant treated with kisspeptin. Patients enrolled in these fertility trials have testified to the improvement in quality of life which the hope of being able to conceive that this alternative to conventional IVF has brought them.
Queen's University Belfast has developed a number of biocatalytic processes for the production of pharmaceutical intermediates which have been applied commercially. The most significant involved Vernakalant, a new drug for treatment of the most common form of irregular heartbeat, now available in the EU, and currently awaiting approval in the USA and Canada. In addition, QUB has sold £300,000 worth of bioproducts and through the collaborations with Almac Sciences facilitated the initiation of their biocatalysis business which currently is a multi-million revenue earner for Almac Sciences and employs 30 staff, including 15 PhD graduates from the Queen's group.
University of Huddersfield research in physical organic chemistry has delivered economic, industrial and societal benefits. It has led to process improvements in chemical manufacturing, most notably in the optimisation of the synthesis of antisense oligonucleotides and in the use of liquid ammonia as a solvent. It has also led to the development of new inhibitors of bacterial β-lactamases for use as antibacterials. The research team's expertise has been reflected in the success of IPOS (Innovative Physical Organic Solutions), a unit established in 2006 to carry out research in process and other areas of chemistry for the chemical industry. IPOS expanded significantly from 2009 to 2013 and has now collaborated with more than 150 companies, many of them based in Yorkshire/Humberside where regeneration is critically dependent on the success of new, non-traditional, high-technology firms and industries. Through these collaborative projects, IPOS has contributed to the growth and prosperity of both regional and national industry.
The Farndale group have identified fragments of collagen, synthesised and assembled in active, triple-helical conformation, for use as ligands to manipulate platelet function. As a result of this work, the fragment Collagen-Related Peptide (CRP) is included in British Committee for Standards in Haematology guidelines as a platelet agonist for the diagnosis of platelet defects. The group has also synthesised triple-helical collagen peptide libraries and used them to map binding of cells or proteins to collagen more widely. The peptides are made and distributed by the Farndale lab, generating income through sales and licencing, and are used internationally by companies and hospitals to develop diagnostics and for high-throughput drug discovery. Prof Farndale also acts as a consultant for companies developing diagnostics.
The impact of this research has been of commercial benefit for TgK Scientific Ltd, a Wiltshire- based SME, who have successfully commercialised a FT-IR Stopped-Flow instrument. This has achieved market share as a result of incorporating an innovative cuvette designed and fabricated by the University of Birmingham's School of Biosciences. The company has sold nine of these instruments since they were first marketed in 2008, generating ~£200,000 in sales. This has made a substantial contribution to the company's total sales, most obviously in 2012 where sales of four instruments accounted for around 10% of their ~£800,000 turnover. The instrument allows the study of fast biological reactions by rapid scanning Fourier Transform Infrared Spectroscopy. The Birmingham contribution is a cuvette of a unique design that enables biological materials to be mixed and observed after 2-3 ms, allowing enzyme-catalysed reactions which have non- chromophoric substrates to be studied in physiological conditions. TgK have combined the cuvette with their stopped-flow drive system and a spectrometer produced by Bruker to make a complete apparatus; it is believed that this gives the instrument a unique functionality valued by a significant niche market.
Bacteria of the Clostridium genus are of pathogenic, medical and industrial importance. Development by University of Nottingham School of Life Science researchers of three patented methods for genetic manipulation of clostridial species has led to licensing agreements for commercial exploitation of the methodology to enhance strains for chemical commodity and biofuel production and for targeted cancer therapy. These methods are providing significant world-wide impact by facilitating commercial R&D investment and technology developments in fields ranging from healthcare, through chemicals manufacture, to the environment.
Based on innovative technology invented and developed through research at the University of Southampton, sustainable pest control products by spinout company Exosect are being employed around the world to preserve the global food supply. Since 2008 its bio-control products have been newly adopted in diverse situations: by Sainsbury's in response to consumer pressure to reduce chemicals in food; by Bayer CropScience, who bought rights, in a multimillion pound deal, to a product for the protection of bee populations; by English Heritage to preserve the UK's cultural heritage. The technology has inspired a US$1m Gates Foundation grant for poverty reduction efforts in sub-Saharan Africa and raised awareness among conventional pesticide manufacturers of the environmental and economic benefits of bio-control solutions.
Work at Birmingham by Peter Knowles and Fred Manby on improving the efficiency of calculating integrals for so-called ab initio calculations, widely used in computational chemistry, has led to a novel, fast algorithm for the accurate calculation of molecular energies and structures. It contains a level of theory, known as MP2, widely used in modelling by industry (pharmaceutical and chemical) as well as in academia. The new local approximation of the method, DF-LMP2, was developed at Birmingham and implemented in the MOLPRO package that has been sold worldwide, generating economic impact. A major attraction of the package is that MOLPRO can do a range of calculations efficiently, MP2 being one of them.
Economic impact is claimed through the growth of the biopharmaceutical spin-out company Q Chip Ltd. During the REF period, this has created 19 new jobs, £7.5M investment, a new Dutch subsidiary (Q Chip BV), and staged-payment, six figure contract sales to four major international pharmaceutical companies.
Q Chip has generated over £928K in contract sales from the pharmaceutical industry from 2008-2012, with further sales of over £1M projected in 2013-14.
Originally established by Professor David Barrow in 2003 from his micro technology research, Q Chip has developed new processes and miniaturised equipment to encapsulate materials, including drugs, within uniform polymeric microspheres as injectable therapeutics.
Radiation sources and amplifiers, in the spectral region from microwave to terahertz, are extensively used in UK industry and public sectors such as security, defence, health and the environment. Companies, including e2v Technologies plc. (e2v) and TMD Technologies Ltd. (TMD), have developed and sold new radiation products based on post-1996 research undertaken at the University of Strathclyde. Their devices accessed new frequency ranges with considerable increases in power and bandwidth. The designs were transferred to industry, where devices have been constructed, jobs created, policy changed and considerable investments made. These sources have had extensive beneficial impact through applications in defence, surveillance, materials processing, health sciences and environmental monitoring.